Fisher & Paykel HealthcareFSPKF +9.59%91 Return-on-Tangible-Asset is 19.10% as of Mar. 2026, which is 1% below its 10-year median of 19.26. GuruFocus rates FSPKF with a GF Score™ of 91/100 and a GF Value™ of $27.32 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 94.61% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Fisher & Paykel Healthcare's annualizedNet Income for the quarter that ended in Mar. 2026 was $299 Mil. Fisher & Paykel Healthcare's average total tangible assets for the quarter that ended in Mar. 2026 was $1,564 Mil. Therefore, Fisher & Paykel Healthcare's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 19.10%.
The historical rank and industry rank for Fisher & Paykel Healthcare's Return-on-Tangible-Asset or its related term are showing as below:
FSPKF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.15 Med: 19.26 Max: 31.24
Current: 18.01
During the past 13 years, Fisher & Paykel Healthcare's highest Return-on-Tangible-Asset was 31.24%. The lowest was 6.15%. And the median was 19.26%.
FSPKF's Return-on-Tangible-Asset is ranked better than 94.61% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs FSPKF: 18.01
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Fisher & Paykel Healthcare Return-on-Tangible-Asset Related Terms
Fisher & Paykel Healthcare Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSPKF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 19.10% mean?
Fisher & Paykel Healthcare (FSPKF) has a Return-on-Tangible-Asset of 19.10% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 19.26. Over the past decade, Fisher & Paykel Healthcare's Return-on-Tangible-Asset has ranged from 6.15 to 31.24. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #46 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 5.4%.
Is Fisher & Paykel Healthcare's Return-on-Tangible-Asset too high?
Fisher & Paykel Healthcare's current Return-on-Tangible-Asset of 19.10% is near median its 10-year median of 19.26. Over the past 10 years, this metric has ranged from a low of 6.15 to a high of 31.24. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Fisher & Paykel Healthcare's value of 19.10% is 3110.1% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #46 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #46 out of 854 companies for Return-on-Tangible-Asset. This places Fisher & Paykel Healthcare in the top 5% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Fisher & Paykel Healthcare's value of 19.10% is 3110.1% above this benchmark. Historically, Fisher & Paykel Healthcare's own Return-on-Tangible-Asset has ranged from 6.15 to 31.24 over the past decade. While the company's 10-year median is 19.26 vs. the industry median of 0.60, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Return-on-Tangible-Asset of 19.10% is 3110.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Return-on-Tangible-Asset is 19.10%, which is near median its own 10-year median of 19.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.32, compared to a current price of $22.52 — trading 17.6% below its estimated fair value. The current Return-on-Tangible-Asset is 19.10%, which is near median its 10-year median of 19.26 and 3110.1% above the Medical Devices & Instruments industry median of 0.60. Fisher & Paykel Healthcare's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current Return-on-Tangible-Asset is 19.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of $22.52 is trading 17.6% below its estimated GF Value™ of $27.32.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FSPKF:
Return-on-Tangible-Asset: 19.10% (near median its 10-year median of 19.26)
GF Value™: $27.32 vs. price of $22.52 (17.6% below fair value)
Industry Position: 3110.1% above the Medical Devices & Instruments median (#46 of 854)
No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
91GF Score
Get the complete analysis for FSPKF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSPKF has been successfully added to your 
